Pollen Counts At Claritin-D Study Sites Undermine 30-Minute Onset Claim
This article was originally published in The Tan Sheet
Executive Summary
The National Advertising Review Board decision shows that firms appealing recommendations by the National Advertising Division sometimes will receive different opinions from the appellate board of appointed experts, which considered appeals by both Bayer and Sanofi's Chattem from a NAD review.
You may also be interested in...
Bayer, Chattem Sneeze At NAD Decision On Claritin And Nasacort Comparison
NAD’s review of Bayer’s Claritin and Claritin-D ads upsets Bayer and challenger Chattem as both appeal the decision to the National Advertising Review Board. Bayer argues it supports the claim nothing “works faster” than Claritin-D, while Chattem says Bayer does not support claiming Claritin-D “starts to work on allergies in 30 minutes.”
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
IFF Narrows Focus To Fragrance, Health, Food
International Flavors & Fragrances agrees to sell its Pharma Solutions business to plant-based ingredients company Roquette for an enterprise value of $2.85bn to reduce debt and streamline its business to three segments, including scents.